Bezlotoxumab cost effective for Clostridium difficile infection

Bezlotoxumab cost effective for Clostridium difficile infection PharmacoEconomics & Outcomes News 792, p6 - 2 Dec 2017 Bezlotoxumab cost effective for Clostridium difficile infection Bezlotoxumab appears to be cost effective for the prevention of recurrent Clostridium difficile infection (CDI), according to findings of a Merck & Co-funded study published in Clinical Infectious Diseases. A Markov model populated with data from the MODIFY I and II trials was used to evaluate the cost effectiveness of bezlotoxumab compared with placebo, in combination with standard of care (SoC) antibacterial therapy, in patients with a mild, moderate or severe episode of CDI. Cost effectiveness was assessed from a US third-party payer perspective over a lifetime time horizon in the overall MODIFY I/II trial population, and in subgroups who were elderly (≥65 years), immunocompromised, with severe CDI, and with one or more CDI episodes in the prior six months. In the total MODIFY population, bezlotoxumab was estimated to gain 0.12 QALYs compared with placebo at an incremental cost of $2444 per patient, resulting in an estimated incremental cost-effectiveness ratio (ICER) of $19 824 per QALY gained. Bezlotoxumab was also cost effective in subgroups of elderly patients, immunocompromised patients and patients with severe CDI, with ICERs of $15 298, $12 597 and $21 430 per QALY gained, respectively. Of note, bezlotoxumab was more cost effective in patients in these subgroups who had one or more previous episodes of CDI, with ICERs of $3591, $4979 and $2983 per QALY gained, respectively. The cost-effectiveness acceptability curve showed that there was 96.7% probability that bezlotoxumab was cost effective at a willingness-to-pay threshold of $50 000 per QALY gained. "Through prevention of recurrent CDI, bezlotoxumab administered together with SoC antibiotics is cost- effective compared with SoC alone," concluded the authors. "Given the urgent population-level threat of CDI identified by the US Centers for Disease Control and Prevention and the limited pharmacotherapy options available to prevent recurrent CDI, bezlotoxumab presents itself as a timely intervention to reduce the burden of recurrent CDI," they commented. * 2015 US dollars Prabhu VS, et al. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection. Clinical Infectious Diseases : 2 Nov 2017. Available from: URL: http://doi.org/10.1093/cid/ cix809 803284213 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Bezlotoxumab cost effective for Clostridium difficile infection

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/bezlotoxumab-cost-effective-for-clostridium-difficile-infection-vQI5dCmICc
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4529-z
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p6 - 2 Dec 2017 Bezlotoxumab cost effective for Clostridium difficile infection Bezlotoxumab appears to be cost effective for the prevention of recurrent Clostridium difficile infection (CDI), according to findings of a Merck & Co-funded study published in Clinical Infectious Diseases. A Markov model populated with data from the MODIFY I and II trials was used to evaluate the cost effectiveness of bezlotoxumab compared with placebo, in combination with standard of care (SoC) antibacterial therapy, in patients with a mild, moderate or severe episode of CDI. Cost effectiveness was assessed from a US third-party payer perspective over a lifetime time horizon in the overall MODIFY I/II trial population, and in subgroups who were elderly (≥65 years), immunocompromised, with severe CDI, and with one or more CDI episodes in the prior six months. In the total MODIFY population, bezlotoxumab was estimated to gain 0.12 QALYs compared with placebo at an incremental cost of $2444 per patient, resulting in an estimated incremental cost-effectiveness ratio (ICER) of $19 824 per QALY gained. Bezlotoxumab was also cost effective in subgroups of elderly patients, immunocompromised patients and patients with severe CDI, with ICERs of $15 298, $12 597 and $21 430 per QALY gained, respectively. Of note, bezlotoxumab was more cost effective in patients in these subgroups who had one or more previous episodes of CDI, with ICERs of $3591, $4979 and $2983 per QALY gained, respectively. The cost-effectiveness acceptability curve showed that there was 96.7% probability that bezlotoxumab was cost effective at a willingness-to-pay threshold of $50 000 per QALY gained. "Through prevention of recurrent CDI, bezlotoxumab administered together with SoC antibiotics is cost- effective compared with SoC alone," concluded the authors. "Given the urgent population-level threat of CDI identified by the US Centers for Disease Control and Prevention and the limited pharmacotherapy options available to prevent recurrent CDI, bezlotoxumab presents itself as a timely intervention to reduce the burden of recurrent CDI," they commented. * 2015 US dollars Prabhu VS, et al. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection. Clinical Infectious Diseases : 2 Nov 2017. Available from: URL: http://doi.org/10.1093/cid/ cix809 803284213 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Access to DeepDyve database
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off